Platelet donor database: a study on the specialist donor database for the patients with alloimmune thrombocytopenia in the Chinese population and the assessment of completeness

作者：Lilan Li, Zhoulin Zhong, Yan Zhou, Heng-Cong Li, Fang Lü, Lihong Jiang, Jierun Chen, Guo-Guang Wu · 发表于：Chinese Medical Journal · 年份：2021 · DOI：10.1097/cm9.0000000000001561 · 被引用次数：4 · 研究领域：Platelet Disorders and Treatments、Blood groups and transfusion、Blood disorders and treatments

To the Editor: Due to the immunogenicity of the platelet antigens, especially blood group antigen (such as ABO antigens), human leukocyte antigen (HLA), human platelet antigen (HPA), and CD36 (platelet glycoproteins IV), which can produce corresponding alloantibodies through immune factors such as blood transfusion, pregnancy, and drugs, the immune reaction of the platelet antigens and antibodies in patients will lead to various types of alloimmune thrombocytopenia, including the immune platelet transfusion refractoriness, post-transfusion purpura, and fetal/neonatal alloimmune thrombocytopenia.[1–4] Platelet transfusion is an effective approach to treat alloimmune thrombocytopenia. Antigen-negative platelets (platelets lacking certain antigens that do not react with the alloantibodies in vivo) are the keys to avoid related alloimmune reactions and achieve satisfactory treatment outcomes of platelet transfusion.[1] To this end, establishing a complete platelet donor database (PDD) that has a suitable number of donors with the known platelet antigens or antigen genotypes and meets the characteristics of platelet immunohematology in the local population is the effective way for the patients with alloimmune thrombocytopenia to quickly find out the antigen-matched platelet donors. The characteristics of the antibodies that mediate the alloimmune thrombocytopenia could be various in different populations as the polymorphisms of antigens and related genes have racial characteristic...